In CML patients, the persistence or occurrence of thrombocytosis, despite WBC decrease and good molecular BCR::ABL1 response under TKI, should alert clinicians to perform molecular screening for Ph-negative MPN, including JAK2, MPL, and CALR mutations. Here, ABL1 is linked to thrombocytosis disease.